EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
MAR 2023
TABLES
123
PAGES
196
EDITION
7
PRICE
USD 4950
CODE
MCP16695
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What`s New for 2023?
»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
»Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
»Online interactive peer-to-peer collaborative bespoke updates
»Access to our digital archives and MarketGlass Research Platform
»Complimentary updates for one year
Looking Ahead to 2023
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Plasma Protease C1-inhibitor Treatment Market to Reach $16.1 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Plasma Protease C1-inhibitor Treatment estimated at US$3.8 Billion in the year 2022, is projected to reach a revised size of US$16.1 Billion by 2030, growing at aCAGR of 20% over the period 2022-2030. C1-Inhibitor, one of the segments analyzed in the report, is projected to record 18.2% CAGR and reach US$7.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Kallikrein Inhibitor (Kalbitor) segment is readjusted to a revised 20.1% CAGR for the next 8-year period.
The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 19.1% CAGR
The Plasma Protease C1-inhibitor Treatment market in the U.S. is estimated at US$1.1 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 19.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.7% and 17.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 14.7% CAGR.
SELECT PLAYERS
AbbVie; Alexion; Argenx; Bluebird Bio; Bristol-Myers Squibb/Celgene; CSL Limited; FibroGen; Gilead; GlaxoSmithKline; Novartis; Pharming Group N.V.; Sanquin; Shire plc; Vertex
SEGMENTS
» Distribution Channel (Hospital Pharmacies, Independent Pharmacies) » Dosage Type (Lyophilized, Liquid/Injectable) » Drug Class (C1-Inhibitor, Kallikrein Inhibitor (Kalbitor), Selective Bradykinin B2 Receptor Antagonist (Firazyr)))
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Plasma Protease C1-inhibitor Treatment – Global Key Competitors Percentage Market Share in 2022 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Plasma Protease C1-inhibitor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for C1-Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for C1-Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for C1-Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Kallikrein Inhibitor (Kalbitor) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Kallikrein Inhibitor (Kalbitor) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Kallikrein Inhibitor (Kalbitor) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Selective Bradykinin B2 Receptor Antagonist (Firazyr)) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Selective Bradykinin B2 Receptor Antagonist (Firazyr)) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Selective Bradykinin B2 Receptor Antagonist (Firazyr)) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Lyophilized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Lyophilized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Lyophilized by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Liquid/Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Liquid/Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Liquid/Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Independent Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Independent Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Independent Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030 |
World Plasma Protease C1-inhibitor Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030 |
III. MARKET ANALYSIS |
UNITED STATES |
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E) |
USA Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
USA Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
USA 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2014, 2023 & 2030 |
USA Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
USA Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
USA 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2014, 2023 & 2030 |
USA Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
USA Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
USA 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2014, 2023 & 2030 |
CANADA |
Canada Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Canada Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Canada 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2014, 2023 & 2030 |
Canada Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Canada Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Canada 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2014, 2023 & 2030 |
Canada Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Canada Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Canada 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2014, 2023 & 2030 |
JAPAN |
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E) |
Japan Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Japan Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Japan 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2014, 2023 & 2030 |
Japan Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Japan Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Japan 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2014, 2023 & 2030 |
Japan Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Japan Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Japan 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2014, 2023 & 2030 |
CHINA |
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E) |
China Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
China Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
China 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2014, 2023 & 2030 |
China Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
China Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
China 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2014, 2023 & 2030 |
China Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
China Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
China 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2014, 2023 & 2030 |
EUROPE |
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E) |
Europe Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2014, 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2014, 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2014, 2023 & 2030 |
FRANCE |
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E) |
France Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
France Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
France 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2014, 2023 & 2030 |
France Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
France Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
France 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2014, 2023 & 2030 |
France Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
France Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
France 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2014, 2023 & 2030 |
GERMANY |
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E) |
Germany Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Germany Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Germany 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2014, 2023 & 2030 |
Germany Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Germany Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Germany 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2014, 2023 & 2030 |
Germany Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Germany Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Germany 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2014, 2023 & 2030 |
ITALY |
Italy Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Italy Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Italy 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2014, 2023 & 2030 |
Italy Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Italy Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Italy 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2014, 2023 & 2030 |
Italy Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Italy Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Italy 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2014, 2023 & 2030 |
UNITED KINGDOM |
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E) |
UK Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
UK Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
UK 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2014, 2023 & 2030 |
UK Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
UK Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
UK 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2014, 2023 & 2030 |
UK Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
UK Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
UK 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2014, 2023 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of Europe 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2014, 2023 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of Europe 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2014, 2023 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of Europe 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2014, 2023 & 2030 |
ASIA-PACIFIC |
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2014, 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2014, 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2014, 2023 & 2030 |
REST OF WORLD |
Rest of World Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of World Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of World 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2014, 2023 & 2030 |
Rest of World Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of World Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of World 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2014, 2023 & 2030 |
Rest of World Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of World Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of World 16-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2014, 2023 & 2030 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com